

Haematologica
HAEMATOL/2020/247015
Version 3

Multiple myeloma: the (r)evolution of current therapy and a glance into
future

Annamaria Gulla and Kenneth C. Anderson

Disclosures: Dr. Anderson serves on advisory boards to Celgene, Millennium, Janssen, Sanofi, Bristol Myers Squibb, Gilead, PrecisionBiosciences, and Tolero, and is a Scientific Founder of OncoPep and C4 Therapeutics. The authors have no other relevant conflict of interest to disclose.

Contributions: Both authors equally contributed.